Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29454416 | 1.00 | MEN1 (0.42) | MEN1LMNAKMT2AKDM4EALOX15 | |
| SCHEMBL11115874 | 0.85 | S100A4 (0.38) | ALDH1A1IDO1TP53 | |
| SCHEMBL11115938 | 0.85 | HSD17B3 (0.38) | MEN1LMNAKMT2AALOX15ALDH1A1 | |
| SCHEMBL11115877 | 0.85 | S100A4 (0.38) | ALDH1A1IDO1TP53 | |
| SCHEMBL11116282 | 0.85 | TRPA1 (0.46) | MEN1KMT2AKDM4EMAPTTRPA1 | |
| SCHEMBL11115316 | 0.85 | HSD17B3 (0.38) | MEN1LMNAKMT2AALOX15ALDH1A1 | |
| SCHEMBL11114767 | 0.85 | TRPA1 (0.46) | MEN1KMT2AKDM4EMAPTTRPA1 | |
| SCHEMBL11118131 | 0.85 | S100A4 (0.38) | ALDH1A1IDO1TP53 | |
| SCHEMBL11116115 | 0.84 | TRPA1 (0.40) | MEN1LMNAKMT2AKDM4EALOX15 | |
| SCHEMBL11111901 | 0.84 | TRPA1 (0.40) | MEN1LMNAKMT2AKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| US-8278329-B2 | Antagonizing N-type calcium channels; use as analgesic, neurodegenerative diseases, brain injury, bronchial asthma, unstable angina and irritable colitis, drug withdrawal symptoms; t-butyl 2-[4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-piperidinyl]-2-oxoethylcarbamate for example | AJINOMOTO CO., INC. (JP) | 2012-10-02 | — | — | US | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110281829-A1 | NOVEL COMPOSITION | IPINTL, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-7713957-B2 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7462630-B2 | Diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2008-12-09 | — | — | US | disclosed |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | AJINOMOTO CO., INC. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1481673-A1 | MEDICINAL COMPOSITIONS CONTAINING GABAPENTIN OR PREGABALIN AND N-TYPE CALCIUM CHANNEL ANTAGONIST | Ajinomoto Co., Inc. (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | AJINOMOTO CO., INC. (JP) | 2004-08-26 | — | — | US | disclosed |
| EP-0338782-A1 | Benzofuran derivatives | MERCK FROSST CANADA INC. (CA) | 1989-10-25 | — | — | EP | disclosed |
| EP-0165810-B1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES, THEIR USE IN INHIBITING MAMMALIAN LEUKOTRIENE BIOSYNTHESIS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES | MERCK FROSST CANADA INC. (CA) | 1989-08-23 | — | — | EP | disclosed |
| EP-0136893-B1 | Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them | MERCK FROSST CANADA INC. (CA) | 1989-08-16 | — | — | EP | disclosed |
| EP-0089759-B1 | DIBENZOCYCLOHEPTENYLIDENE COMPOUNDS FOR USE IN MODULATING THE IMMUNE RESPONSE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-04-09 | — | — | EP | disclosed |
| EP-0035903-B1 | DIBENZOCYCLOHEPTENYLIDENES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-10-17 | — | — | EP | disclosed |
| EP-0089759-A1 | Dibenzocycloheptenylidene compounds for use in modulating the immune response | AMERICAN HOME PRODUCTS CORPORATION (US) | 1983-09-28 | — | — | EP | disclosed |
| US-4376124-A | Method for modulating the immune response with dibenzocycloheptenylidenes | AMERICAN HOME PRODUCTS CORPORATION (US) | 1983-03-08 | — | — | US | disclosed |
| WO-1981002519-A1 | METHOD FOR TREATING INFLAMMATION | AMERICAN HOME PROD (US) | 1981-09-17 | — | — | WO | disclosed |
| EP-0035903-A1 | Dibenzocycloheptenylidenes and their use in pharmaceutical compositions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-09-16 | — | — | EP | disclosed |
| US-4267192-A | BY ADMINISTERING AN UNSATURATED DIBENZOCYCLOHEPTENE ACID OR ESTER COMPOUND | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009814-A1 | Pharmaceutical composition containing gabapentin or pregabalin and N-type calcium channel antagonist | CACNA1B, CACNA1G, CACNA1C | MEN1 2573/4885LMNA 1363/4885KMT2A 4191/4885 |
| US-20040167118-A1 | Novel diarylalkene derivatives and novel diarylalkane derivatives | CACNA1E, CACNA1H, CACNA1D | MEN1 2030/4885LMNA 1902/4885KMT2A 1415/4885 |
| US-20080058311-A1 | NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES | CACNA1E, CACNA1D, CACNA1H | MEN1 2266/4885LMNA 1915/4885KMT2A 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.